Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model
Van Name M, Klingensmith G, Nelson B, Wintergerst K, Mitchell J, Norris K, Tamborlane W, Clements M, Hannon T, Shoemaker A, Wood J, Gal R. Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model. Diabetes Technology & Therapeutics 2020, 22: 330-336. PMID: 31859529, PMCID: PMC7869879, DOI: 10.1089/dia.2019.0448.Peer-Reviewed Original ResearchConceptsPediatric Diabetes ConsortiumType 2 diabetesClinical centersCoordinating CenterPediatric treatment centerPediatric type 1 diabetesPhase 3 trialType 2 Diabetes StudyType 1 diabetesPediatric Type 2Diabetes-related studiesTreatment of youthPivotal trialsRandomized subjectsDiabetes StudyStudy protocolClinical trialsContract research organizationsConsortium modelTreatment centersType 2DiabetesNew drugsTrialsEnrollment strategiesChildren and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis